Stomach cancer breakthrough: study seeks best Post-Surgery care for complete responders
NCT ID NCT07161453
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at 500 stomach cancer patients who had chemotherapy plus immunotherapy before surgery and achieved a complete response (no cancer left in the removed tissue). It compares different post-surgery treatments, including chemotherapy alone or with immunotherapy, to see which is better at preventing cancer from coming back. The goal is to find the safest and most effective follow-up plan for these patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Chemotherapy (SOX or XELOX) with or without a PD-1 inhibitor (immunotherapy)
What this could lead to
If successful, this could help identify the best post-surgery treatment to prevent cancer recurrence in patients who already had a strong response to pre-surgery therapy.
What could go wrong
This is a real-world study, not a tightly controlled trial, so results may be less definitive. The treatments have side effects like fatigue, nausea, and immune-related reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.